综述
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Antonio Ceriello, Francesco Prattichizzo, Abdul Raouf Mastan Sheik Abdullah, Rosalba La Grotta, Cesare Berra, Barbara M. McGowan, Alicia Jenkins, Neale D. Cohen 等 10 位
MultiMedica University of Messina St Thomas' Hospital Guy's and St Thomas' NHS Foundation Trust
来源Nature Reviews Endocrinology
年份2026
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
摘要 · 节选
暂未获取摘要。可打开原文或 PDF，后续可基于全文生成更完整的速读。
逐年被引趋势
840
826
关键指标
8
被引次数 · OpenAlex
14.59
领域内被引倍数
同类平均 = 1
同类平均 = 1
前 0.7%
引用位次
同领域 · 同年份 · 同类型
同领域 · 同年份 · 同类型
149
参考文献
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：文献信息
论文问答
当前基于文献信息回答
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学Diabetes Treatment and Management
Pharmacology and Obesity Treatment · Diabetes Management and Research
参考文献 149
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
被引 2,708Xavier Pi-Sunyer, Arne Vernon Astrup, Ken Fujioka · New England Journal of Medicine · 2015
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
被引 1,191Melanie Jane Davies, Richard M. Bergenstal, Bruce W. Bode · JAMA · 2015
Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk?
被引 256J-P Montani, Y. Schutz, Abdul G. Dulloo · Obesity Reviews · 2015
此处列出前 3 条
引用本文 8
Lipid Metabolic Disorders: a Pivotal Driver in Type 2 Diabetes Mellitus Pathogenesis
被引 4Junqi Wu, Huabin Wang, Miao Fu · Current Obesity Reports · 2026
Emerging therapies for knee osteoarthritis
被引 0Alice Courties, Tobias Winkler, Philip G. Conaghan · Nature Reviews Rheumatology · 2026
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
被引 0Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic · Diabetes Therapy · 2026
按被引量排序，此处列出前 3 条